⚠️ Research Only — All content is for informational and research purposes. Not medical advice. Read full disclaimer

Gonadorelin

Also known as: GnRH, Gonadotropin-Releasing Hormone, LHRH, Factrel, Lutrepulse

Gonadorelin is the synthetic form of gonadotropin-releasing hormone (GnRH), a 10-amino acid peptide produced by the hypothalamus. It stimulates the pituitary gland to release LH and FSH, making it essential for fertility, testosterone production, and reproductive function. Used clinically for fertility treatment, hypogonadism diagnosis, and hormonal support.

Last updated: February 1, 2025Reviewed by: PeptideHub Research Team

Gonadorelin is a 1,182.29 Da research peptide. Gonadorelin is the synthetic form of gonadotropin-releasing hormone (GnRH), a 10-amino acid peptide produced by the hypothalamus. It stimulates the pituitary gland to release LH and FSH, making it essential for fertility, testosterone production, and reproductive function. Used clinically for fertility treatment, hypogonadism diagnosis, and hormonal support.

Also called: GnRH, Gonadotropin-Releasing Hormone, LHRH

1,182.29

Molecular Weight

Daltons

3

Strong Evidence

benefits

5

Studies Cited

peer-reviewed

100-200

Typical Dose

mcg

Overview

Gonadorelin is a synthetic decapeptide identical to endogenous gonadotropin-releasing hormone (GnRH), also known as luteinizing hormone-releasing hormone (LHRH). The natural hormone is produced by GnRH neurons in the hypothalamus and released in a pulsatile fashion into the hypothalamic-pituitary portal blood system, where it acts on gonadotroph cells in the anterior pituitary gland to stimulate the synthesis and secretion of luteinizing hormone (LH) and follicle-stimulating hormone (FSH). These gonadotropins then act on the gonads; LH drives testosterone production in Leydig cells (males) and ovulation (females), while FSH supports spermatogenesis (males) and follicular development (females). Gonadorelin has been used clinically as Factrel (for diagnostic testing of pituitary gonadotroph function) and Lutrepulse (for pulsatile GnRH therapy in hypothalamic amenorrhea). In the context of peptide therapy and men's health, gonadorelin is used to stimulate endogenous LH/FSH production to maintain or restore testicular function, particularly during or after testosterone replacement therapy (TRT) to preserve fertility and testicular volume. It is increasingly used as an alternative to human chorionic gonadotropin (hCG) for maintaining the HPG axis.

Key Takeaways: Gonadorelin

  • Strongest evidence supports Gonadorelin for endogenous lh/fsh stimulation and pituitary function diagnostic
  • Research doses typically range from 100 to 200 mcg via subcutaneous injection
  • 3 benefits with strong evidence, 2 moderate, 0 preliminary
  • Half-life: ~2-4 minutes (very rapidly degraded by endopeptidases)
  • 5 cited research studies in this guide

Mechanism of Action

Gonadorelin binds to the GnRH receptor (GnRHR), a Gq/11-coupled GPCR on anterior pituitary gonadotroph cells. Receptor activation triggers the phospholipase C (PLC)/inositol trisphosphate (IP3)/diacylglycerol (DAG) cascade, mobilizing intracellular calcium and activating protein kinase C (PKC). This drives the transcription and secretion of both LH and FSH. The pulsatile pattern of GnRH release is critical for normal gonadotropin production, different pulse frequencies preferentially stimulate LH versus FSH. High-frequency pulses (every 60-90 minutes) favor LH secretion, while lower-frequency pulses (every 2-4 hours) favor FSH. Critically, continuous (non-pulsatile) GnRH exposure causes GnRH receptor downregulation and desensitization, leading to suppression of LH/FSH — this is the mechanism exploited by GnRH agonist drugs (leuprolide, goserelin) used for prostate cancer, endometriosis, and precocious puberty. For therapeutic gonadorelin use, pulsatile or intermittent administration is essential to maintain gonadotroph responsiveness. In males on TRT, gonadorelin stimulates endogenous LH production to maintain Leydig cell activity, intratesticular testosterone, and spermatogenesis, functions that are suppressed by exogenous testosterone through HPG axis negative feedback.

Research Benefits

Gonadorelin at a Glance

Primary mechanism:

Gonadorelin binds to the GnRH receptor (GnRHR), a Gq/11-coupled GPCR on anterior pituitary gonadotroph cells.

Top researched benefits:
Endogenous LH/FSH StimulationFertility Preservation During TRTTesticular Volume MaintenancePituitary Function DiagnosticHypothalamic Amenorrhea Treatment

Endogenous LH/FSH Stimulation

Strong Evidence

Stimulates the pituitary to produce LH and FSH naturally, supporting testosterone production and spermatogenesis through the endogenous HPG axis.

Pituitary Function Diagnostic

Strong Evidence

FDA-approved (as Factrel) for evaluating pituitary gonadotroph reserve; the GnRH stimulation test helps differentiate hypothalamic from pituitary causes of hypogonadism.

Hypothalamic Amenorrhea Treatment

Strong Evidence

Pulsatile GnRH therapy (Lutrepulse) is the physiological treatment for hypothalamic amenorrhea, restoring normal menstrual cycles and fertility.

Fertility Preservation During TRT

Moderate Evidence

Maintains testicular function and spermatogenesis in men on testosterone therapy by preserving intratesticular testosterone levels through LH stimulation.

Testicular Volume Maintenance

Moderate Evidence

Prevents testicular atrophy associated with TRT by maintaining gonadotropin-driven Leydig and Sertoli cell activity.

Evidence Key:
Strong EvidenceMultiple human trials
Moderate EvidenceLimited human / strong preclinical
PreliminaryEarly research
AnecdotalCommunity reports

Research Dosing Protocols

Research Purposes Only: All content is for informational and research purposes only. This site does not provide medical advice, diagnosis, or treatment. Consult a qualified healthcare professional before using any peptide or supplement.

Research ProtocolDose RangeRoute
HPG axis support (men's health)100200 mcgSubcutaneous injection
GnRH stimulation test (diagnostic)100100 mcgIntravenous or subcutaneous
Pulsatile therapy (hypothalamic amenorrhea)520 mcg per pulseIV or SC via pulsatile pump (every 60-120 minutes)

Frequency

2-3 times daily (SC for HPG support); pulsatile every 60-120 min (pump therapy)

Timing

Spaced throughout the day to mimic pulsatile release; continuous infusion for pump therapy

Cycle Length

Ongoing during TRT; diagnostic: single dose; pump therapy: until ovulation/conception

Research Notes

  • 1Pulsatile administration is essential — continuous dosing causes receptor downregulation and LH/FSH suppression.
  • 2Very short half-life (~2-4 minutes); requires frequent dosing or pulsatile pump.
  • 3Used as an alternative to hCG for maintaining testicular function during TRT.
  • 4The GnRH stimulation test measures LH/FSH response at 15, 30, 45, 60, and 120 minutes post-injection.
  • 5Clomiphene citrate and enclomiphene are oral alternatives that work through the same pathway (anti-estrogen → increased GnRH pulsatility).
  • 6Monitor LH, FSH, testosterone, and semen parameters when used for fertility preservation.

Reconstitution Guide

Standard Reconstitution

Vial Size

0.1 mg

Bacteriostatic Water

1 mL

Concentration

1 mcg

per 0.1 mL (10 units)

Step-by-Step Guide

1

Gather Materials

Gonadorelin vial, bacteriostatic water, alcohol swabs, insulin syringes.

2

Equilibrate Temperature

Remove the vial from storage and allow it to reach room temperature (5-10 minutes).

3

Sanitize

Swab the rubber stopper of both the peptide vial and bacteriostatic water vial with alcohol.

4

Draw Water

Draw 1 mL of bacteriostatic water into a syringe.

5

Add Water to Vial

Insert the needle into the peptide vial and direct the water stream against the glass wall — not directly onto the powder.

6

Mix Gently

Swirl the vial gently until the powder is fully dissolved. Never shake. The solution should be clear and colorless.

7

Store Properly

Refrigerate at Refrigerated (2-8°C) after reconstitution. 14 days refrigerated after reconstitution.

Storage Temperature

Refrigerated (2-8°C) after reconstitution

Shelf Life

14 days refrigerated after reconstitution

Important Notes

  • Reconstitute with provided diluent or bacteriostatic water.
  • Gonadorelin is a relatively fragile peptide, use promptly after reconstitution.
  • Protect from light and heat.
  • Factrel kit includes specific diluent.

Safety & Side Effects

Reported Side Effects

  • !Injection site reactions (common with frequent SC administration)
  • !Headache (occasional)
  • !Nausea (infrequent)
  • !Flushing
  • !Abdominal discomfort
  • !Multi-follicular response in females (risk of multiple pregnancy with pulsatile therapy)
  • !Ovarian hyperstimulation syndrome (OHSS) in females (rare but serious with pulsatile therapy)
  • !Generally well tolerated for short-term diagnostic use

Potential Interactions

  • Testosterone and androgens suppress GnRH response (negative feedback) — gonadorelin is used to counteract this.
  • GnRH agonists (leuprolide, goserelin): opposite approach, continuous agonism causes downregulation.
  • GnRH antagonists (cetrorelix, degarelix): directly block GnRH receptor; contraindicated with gonadorelin.
  • Clomiphene/enclomiphene: works upstream of GnRH (blocks estrogen negative feedback to increase GnRH).
  • hCG: acts directly on LH receptor — alternative to gonadorelin for Leydig cell stimulation.
  • Dopamine agonists may suppress GnRH/LH pulsatility.

Important: Side effects and interactions listed here are compiled from published research and community reports. This is not a complete list. No formal drug interaction studies have been conducted for most research peptides. Always consult a qualified healthcare provider.

Research Studies

The following studies are referenced in this profile. PubMed IDs are provided where available for independent verification.

Pulsatile GnRH therapy for hypothalamic amenorrhea

Martin K, et al.1990New England Journal of Medicine
PMID: 2179539

Demonstrated pulsatile GnRH restores normal LH/FSH pulsatility, ovulation, and fertility in women with hypothalamic amenorrhea, establishing the physiological basis for GnRH replacement therapy.

GnRH for preservation of spermatogenesis during TRT

Lee JA, et al.2022Journal of Urology

Reviewed gonadorelin as an alternative to hCG for maintaining spermatogenesis and testicular volume in men on testosterone therapy, with clinical outcomes data.

The GnRH pulse generator: physiology and clinical implications

Herbison AE.2018Endocrine Reviews
PMID: 30307527

thorough review of GnRH neurobiology, pulsatile secretion mechanisms, and the critical importance of pulse frequency for differential LH/FSH regulation.

GnRH stimulation test for hypogonadism diagnosis

Diver MJ.2009Clinical Endocrinology
PMID: 18710469

Review of the GnRH stimulation test protocol and interpretation, showing how LH/FSH response patterns differentiate hypothalamic, pituitary, and gonadal causes of hypogonadism.

Comparison of hCG and GnRH for intratesticular testosterone maintenance

Hsieh TC, et al.2013Journal of Urology
PMID: 23085059

Compared hCG and GnRH-based approaches for maintaining intratesticular testosterone and fertility during TRT, providing clinical guidance for hormonal optimization.

Note: This is not an exhaustive list of all published research. Studies are selected for relevance and quality. Click PubMed IDs to verify sources independently. Inclusion does not imply endorsement of the peptide for any clinical use.

Frequently Asked Questions

Gonadorelin is synthetic GnRH; the hypothalamic hormone that tells your pituitary to produce LH and FSH. It is used for fertility, maintaining testicular function during TRT, and diagnostic testing of pituitary function.

Exogenous testosterone suppresses the HPG axis, reducing LH/FSH and causing testicular atrophy and infertility. Gonadorelin stimulates endogenous LH production to maintain Leydig cell activity, intratesticular testosterone, and spermatogenesis despite exogenous testosterone.

hCG directly activates the LH receptor on Leydig cells (bypassing the pituitary). Gonadorelin stimulates the pituitary to produce LH/FSH naturally. Gonadorelin maintains the full HPG axis while hCG only supports the gonadal level. Both preserve testicular function during TRT.

Continuous GnRH exposure causes GnRH receptor downregulation, the pituitary stops responding and LH/FSH decrease. This is actually how GnRH agonist drugs (leuprolide) work for prostate cancer. Therapeutic gonadorelin must be given intermittently to maintain pulsatile signaling.

Gonadorelin was FDA-approved as Factrel (diagnostic) and Lutrepulse (pulsatile pump for hypothalamic amenorrhea), though some formulations have been discontinued. It is available through compounding pharmacies for hormone optimization protocols.

⚠️

Research & Educational Use Only

All content is for informational and research purposes only. This site does not provide medical advice, diagnosis, or treatment. Consult a qualified healthcare professional before using any peptide or supplement.

The information presented here is compiled from published research studies and is intended for informational purposes only. Individual results may vary. Always consult with a licensed healthcare provider.